Article

Segment 6: Setting the Bar for Hepatitis C Treatment Costs

Even with 2 drugs competing with one another and more coming soon, Ed Cohen, PharmD, FAPhA, does not believe additional competition in the marketplace will significantly drive down costs for a hepatitis C cure.

Even with 2 drugs competing with one another and more coming soon, Ed Cohen, PharmD, FAPhA, does not believe additional competition in the marketplace will significantly drive down costs for a hepatitis C cure.

“This product is needed,” he explained and added that the product is only used for a short period of time and it’s a cure. “The overall therapy to save a life—how do you put a price on it?”

Although Express Scripts has been in discussion with companies making other hepatitis C products, Steven Miller, MD, MBA, said it will be hard for any new product to be better than what is already available. The big opportunity is to develop a product treating more than genotypes 1 and 4, which the current products are recommended for.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo